The Empirical Research On Mergers And Acquisitions Effects Of Biomedical Listed Companies

Biomedical Listed ComPanies has the characteristics of high-tech,high input,long periodicity,high profit and high risk.The chinese government has given policy support to Biomedical industry,making it more competitive.As an important strategy,M&A is the only viable route to intergrate advantage resources,get high-quality capital,promote industrial structure adjustment, optimize the allocation of resources and tend towards internationalization for Biomedical Listed ComPanies. The measurement of success in M&A is Whether Biomedical Listed ComPanies achieve intentions including more efficiency, maximising profits of company and benefit of stockholder,intergrate advantage resources after M&A.There are massive authoritative data about financial indicators of Biomedical Listed ComPanies in this paper.Based on the individual case of Shanghai Pharma’M&A,this paper has analysed the short-term M&A effects applying the method of factor analysis and statistics.Also,this paper has predicted the effects model of Shanghai Pharma from the year of2013to2015.And then,the effects of Biomedical Listed ComPanies which has been divided into two part(M&A and NON-M&A) in china has comprehensively analyzed.In our opinion,the short-term M&A effects of Shanghai Pharma is negative with a below average score in Biomedical industry.The critical reason is that there are more costs of management,operation and so on.Through the achievement of M&A, Shanghai Pharma has improved the levels of inventory,market,short-term and long-term solvency,While long-term solvency will grow more slowly;The M&A effects of biomedical industry in china has higher level.Net profit has more increased,while the decline in level of market,inventory,short-term solvency and the increased costs of management,operation and so on is the critical point.